Skip to main content
PT-141 Medicinal

Chemistry, delivery, human consequences

PT-141 results after 24 weeks

An engineered ring can help a peptide survive. The more demanding question is whether the resulting medicine brings enough relief to matter.

Phase 3 results

The two matching RECONNECT trials enrolled 1,267 premenopausal women with HSDD. Participants received bremelanotide 1.75 mg beneath the skin as needed or placebo over 24 weeks. The published Phase 3 results reported improvements on both primary measures:

  • Sexual desire: integrated FSFI-desire difference of +0.35 versus placebo, P<.001.
  • Distress over low desire: integrated FSDS-DAO item 13 difference of -0.33 versus placebo, P<.001.

FSFI is the Female Sexual Function Index. The other measure asks about distress related to sexual desire. These scores describe different outcomes, so their numerical sizes cannot be compared as though they share a single scale.

I accept that the trials detected an effect. The medicinal question I still wrestle with is its value: how much easier did life become for the women whose scores improved? A small average difference leaves that experience incompletely described.

The clinical-meaningfulness debate

Spielmans’s 2024 critique of effect sizes and outcome measures questions how much practical relief the reported changes establish. A medicine intended to relieve distress owes a clear account of that relief; I agree with the demand. Statistical evidence of a difference and the felt worth of that difference are separate judgments.

The 2026 systematic review and meta-analysis found improvements in total Female Sexual Function Index scores, desire and arousal subscales, and distress with bremelanotide. That supports benefit across the pooled trial evidence. It also leaves room for disagreement about the magnitude of relief. My own position is cautious: the positive findings merit acknowledgment, with their modest size kept visible.

Long-term follow-up

The open-label extension enrolled 684 women for up to 52 weeks. Sexual-desire improvements were sustained and no new safety signals emerged. Nausea, flushing and headache remained the most common drug-related adverse events. Everyone knew the treatment they received, and there was no placebo group for the extension.

For me, that design makes this chiefly a continuation and tolerability story. Sustained improvement is encouraging among the women followed; the absence of a new signal gives the follow-up value without settling every long-term risk. The reasons treatment became difficult sit alongside the gains on the effects page.